Area of research
Statistics and Probability · Pulmonary and Respiratory Medicine
Research interest
Research interests include Statistical Methods in Clinical Trials, Renal cell carcinoma treatment, Cancer Immunotherapy and Biomarkers, and Advanced Causal Inference Techniques.
Win statistics (win ratio, win odds, and net benefit): Noncollapsibility and standardization for randomized clinical trials.
Adjusted win ratio using the inverse probability of treatment weighting.
An IPCW Adjusted Win Statistics Approach in Clinical Trials Incorporating Equivalence Margins to Define Ties.
Design and sample size determination for multiple-dose randomized phase II trials for dose optimization.
Avelumab First-Line Maintenance for Advanced Urothelial Carcinoma: Results From the JAVELIN Bladder 100 Trial After ≥2 Years of Follow-Up
Avelumab First-Line Maintenance for Advanced Urothelial Carcinoma: Results From the JAVELIN Bladder 100 Trial After ≥2 Years of Follow-Up.
Avelumab First-line Maintenance Therapy for Advanced Urothelial Carcinoma: Comprehensive Clinical Subgroup Analyses from the JAVELIN Bladder 100 Phase 3 Trial
Win statistics (win ratio, win odds, and net benefit) can complement one another to show the strength of the treatment effect on time-to-event outcomes.
The stratified win statistics (win ratio, win odds, and net benefit)
Adjusted win ratio using the inverse probability of treatment weighting
The stratified win statistics (win ratio, win odds, and net benefit).
The win odds: statistical inference and regression.
Evidence synthesis analysis with prioritized benefit outcomes in oncology clinical trials.
Comparing Short- and Long-Term Treatment Duration of Bevacizumab for Advanced Ovarian Cancer.
Win statistics (win ratio, win odds, and net benefit) can complement one another to show the strength of the treatment effect on time‐to‐event outcomes
Association of Neutrophil-to-Lymphocyte Ratio with Efficacy of First-Line Avelumab plus Axitinib vs. Sunitinib in Patients with Advanced Renal Cell Carcinoma Enrolled in the Phase 3 JAVELIN Renal 101 Trial.
Utilizing restricted mean duration of response for efficacy evaluation of cancer treatments.
Efficacy and correlative analyses of avelumab plus axitinib versus sunitinib in sarcomatoid renal cell carcinoma: post hoc analysis of a randomized clinical trial
Association of Neutrophil-to-Lymphocyte Ratio with Efficacy of First-Line Avelumab plus Axitinib vs. Sunitinib in Patients with Advanced Renal Cell Carcinoma Enrolled in the Phase 3 JAVELIN Renal 101 Trial
Adjusting win statistics for dependent censoring.
Avelumab in relapsed/refractory classical Hodgkin lymphoma: phase 1b results from the JAVELIN Hodgkins trial.
Dihydromyricetin Ameliorates Inflammation-Induced Insulin Resistance via Phospholipase C-CaMKK-AMPK Signal Pathway
Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma
On the empirical choice of the time window for restricted mean survival time.
The inverse-probability-of-censoring weighting (IPCW) adjusted win ratio statistic: an unbiased estimator in the presence of independent censoring.
Whole genome sequence analysis reveals genetic structure and X-chromosome haplotype structure in indigenous Chinese pigs
Analysis of Response Data for Assessing Treatment Effects in Comparative Clinical Studies.
The win ratio: Impact of censoring and follow-up time and use with nonproportional hazards.
Evaluation of brain metastasis in JAVELIN Renal 101: Efficacy of avelumab + axitinib (A+Ax) versus sunitinib (S).
Accuracy of genomic prediction using mixed low-density marker panels